ScholarLens Back to search
2013•Journal of Health ResearchRequires access

Distribution And Emergence Of Chloroquine-Resistant Plasmodium Vivax

Kanchana Rungsihirunrat, Jiraporn Kuesap, Wanna Chai่jaroenkul, Kesara Na‐Bangchang

Open publisher page 0 citations

Abstract

Plasmodium vivax is the second most geographically widespread human malaria parasite. The global burden of P. vivax malaria is approximately 70-80 million cases annually. Chloroquine given together with primaquine is currently the first-line treatment for P. vivax .  P. vivax resistance to chloroquine has however been reported in several endemic areas, particularly Southeast Asia, the area with the greatest P. vivax burden. Emergence of chloroquine-resistant P. vivax (CRPV) imposes a significant impact on the control strategies and treatment policies in these endemic regions.

About this research paper

What this paper is about

Plasmodium vivax is the second most geographically widespread human malaria parasite. The global burden of P. vivax malaria is approximately 70-80 million cases annually. Chloroquine given together with primaquine is currently the first-line treatment for P. vivax .  P. vivax resistance to chloroquine has however been reported in several endemic areas, particularly Southeast Asia, the area with the greatest P. vivax burden. Emergence of chloroquine-resistant P. vivax (CRPV) imposes a significant impact on the control strategies and treatment policies in these endemic regions.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Plasmodium vivax is the second most geographically widespread human malaria parasite. The global burden of P. vivax malaria is approximately 70-80 million cases annually. Chloroquine given together with primaquine is currently the first-line treatment for P. vivax .  P. vivax resistance to chloroquine has however been reported in several endemic areas, particularly Southeast Asia, the area with the greatest P. vivax burden. Emergence of chloroquine-resistant P. vivax (CRPV) imposes a significant impact on the control strategies and treatment policies in these endemic regions.

Key concepts: Primaquine, Plasmodium vivax, Chloroquine, Malaria, Vivax malaria, Piperaquine, Virology, Biology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Distribution And Emergence Of Chloroquine-Resistant Plasmodium Vivax — Research Paper | ScholarLens